The FDA on January 19, 2023, granted accelerated approval to TUKYSA® in combination with Trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following Fluoropyrimidine, Oxaliplatin, and Irinotecan-based chemotherapy. TUKYSA® is a product of Seagen Inc.
Other Pages – Top Ad
Advertisement